An audit of treatment focussed BRCA1/2 mutation testing at an integrated Familial Cancer Clinic

Background The growth of a personalised approach to cancer treatment including surgical risk management strategies and Parp Inhibitor trials for BRCA1/2 mutation carriers has lead to the Peter MacCallum Familial Cancer Centre experiencing a rapidly increased demand for expedited risk assessment appointments +/BRCA1/2 mutation testing. Expedited BRCA mutation screens are offered to individuals assessed eligible for publically funded testing and require these results in a defined time period to assist in their current cancer management. The demand for expedited services places a burden on both the laboratory and clinic as patients need to be seen at short notice and have their genetic test take priority over routine tests.